

INC Research Holdings, Inc.
Form DEFA14A
May 11, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-11(c) or §240.14a-12

INC RESEARCH HOLDINGS, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

- (1) Title of each class of securities to which transaction applies:

- (2) Aggregate number of securities to which transaction applies:

- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

- (4) Proposed maximum aggregate value of transaction:

- (5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

- (1) Amount Previously Paid:

- (2) Form, Schedule or Registration Statement No.:

- (3) Filing Party:

(4) Date Filed:

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

On May 10, 2017, INC Research Holdings, Inc. (the Company) held an investor call relating to the transactions contemplated by the Agreement and Plan of Merger, dated May 10, 2017, between the Company and Double Eagle Parent, Inc., a Delaware corporation (inVentiv), the indirect parent company of inVentiv Group Holdings, Inc. The Company made available on the investor relations section of its website an investor presentation for reference during such call. The following is a revised copy of the investor presentation. Through inadvertent error, the Company left out slides 36-38, which contain second quarter 2017 guidance and a full year 2017 reconciliation. The Company has revised the investor presentation to include slides 36-38. Additionally, on slide 25, the Company is clarifying that there are multiple clinical operational systems available for consideration for consolidation.

INC Research + inVentiv Health Merger Creating a Leading Global Biopharmaceutical Solutions Organization May 10, 2017

Important Information Forward-Looking Statements This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such forward-looking statements reflect, among other things, our current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “projects,” “should,” “would,” “targets,” “will” and similar words and expressions are intended to identify forward-looking statements. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the potential timing or consummation of the proposed transaction or the anticipated benefits thereof, including, without limitation, future financial and operating results. INC Research and inVentiv Health caution readers that these and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to risks and uncertainties related to (i) the ability to obtain shareholder and regulatory approvals, or the possibility that they may delay the transaction or that such regulatory approval may result in the imposition of conditions that could cause the parties to abandon the transaction, (ii) the risk that a condition to closing of the merger may not be satisfied (iii) the ability of INC Research and inVentiv Health to integrate their businesses successfully and to achieve anticipated synergies, (iv) the possibility that other anticipated benefits of the proposed transaction will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of the new combined company’s operations, and the anticipated tax treatment, (v) potential litigation relating to the proposed transaction that could be instituted against INC Research, inVentiv Health or their respective directors, (vi) possible disruptions from the proposed transaction that could harm INC Research’s and/or inVentiv Health’s business, including current plans and operations, (vii) the ability of INC Research or inVentiv Health to retain, attract and hire key personnel, (viii) potential adverse reactions or changes to relationships with clients, employees, suppliers or other parties resulting from the announcement or completion of the merger, (ix) potential business uncertainty, including changes to existing business relationships, during the pendency of the merger that could affect INC Research’s or inVentiv Health’s financial performance, (x) certain restrictions during the pendency of the merger that may impact INC Research’s or inVentiv Health’s ability to pursue certain business opportunities or strategic transactions, (xi) continued availability of capital and financing and rating agency actions, (xii) legislative, regulatory and economic developments and (xiii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the proxy statement that will be filed with the Securities and Exchange Commission in connection with the proposed transaction. While the list of factors presented here is, and the list of factors to be presented in the proxy statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on INC Research’s or inVentiv Health’s consolidated financial condition, results of operations, credit rating or liquidity. Unless legally required, neither INC Research nor inVentiv Health assumes any obligation to update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information. **Additional Information and Where to Find It** This communication is being made in respect of the proposed merger transaction involving the INC Research and inVentiv Health. In connection with the proposed transaction, INC Research will file with the Securities and Exchange Commission a proxy statement and will mail the proxy statement to its shareholders. Shareholders are encouraged to read the proxy statement regarding the proposed transaction in its entirety when it becomes available

and before making any voting decision as it will contain important information about the transaction. Shareholders will be able to obtain a free copy of the proxy statement (when available), as well as other filings made by INC Research regarding INC Research, inVentiv Health, and the proposed transaction, without charge, at the Securities and Exchange Commission's website (<http://www.sec.gov>) or at INC Research's website (investor.incresearch.com). Participants in the Solicitation INC Research and its respective executive officers, directors and other persons may be deemed to be participants in the solicitation of proxies from INC Research's shareholders with respect to the special meeting of shareholders that will be held to consider and vote upon the approval of the share issuance and the proposed transaction. Information regarding the officers and directors of INC Research is included in its Annual Report on Form 10-K for the year ended Dec. 31, 2016, and INC Research's notice of Annual Meeting of Shareholders and Proxy Statement, which were filed with the Securities and Exchange Commission on April 13, 2017. Other information regarding the participants in the solicitation and a description of their direct and indirect interests, by security holdings or otherwise, which may be different than those of INC Research's shareholders generally, will be contained in the proxy statement (when filed) and other relevant materials to be filed with the Securities and Exchange Commission in connection with the proposed transaction. This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Important Information (Cont'd) Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with GAAP, this presentation contains certain non-GAAP financial measures, including Adjusted Income from Operations, Adjusted Operating Margin, Adjusted Net Income (including Adjusted Diluted Earnings per Share), EBITDA and Adjusted EBITDA. Both INC Research's and inVentiv Health's financial statements and the associated non-GAAP measures have been prepared in accordance with their historical accounting and reporting policies. The combined company has not yet determined the conforming policy or adjustments that it will make upon consummation of this merger. A "non-GAAP financial measure" is generally defined as a numerical measure of a company's financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with GAAP in the statements of operations, balance sheets or statements of cash flows of the Company. The Company defines Adjusted Income from Operations as income from operations excluding expenses and transactions that the Company believes are not representative of its core operations, namely, acquisition-related amortization; restructuring, CEO transition, and other costs; transaction expenses; share-based compensation expense; and contingent consideration related to acquisitions and other expense. The Company defines Adjusted Operating Margin as adjusted income from operations as a percentage of net service revenue. The Company defines Adjusted Net Income (including Adjusted Diluted Earnings per Share) as net income (including diluted earnings per share) excluding the items excluded from adjusted income from operations mentioned previously and other expense. After giving effect to these items and other unusual tax impacts during the period, the Company has also included an adjustment to its income tax rate to reflect the expected long-term income tax rate. EBITDA represents earnings before interest, taxes, depreciation and amortization. The Company defines Adjusted EBITDA as EBITDA, further adjusted to exclude certain expenses and transactions that the Company believes are not representative of its core operations, namely, restructuring, CEO transition, and other costs; transaction expenses; share-based compensation expense; contingent consideration related to acquisitions and other expense; and other expense. The Company presents EBITDA and Adjusted EBITDA because it believes they are useful metrics for investors as they are commonly used by investors, analysts and debt holders to measure the Company's ability to fund capital expenditures and meet working capital requirements. Each of the non-GAAP measures noted above are used by management and the Board to evaluate the Company's core operating results as they exclude certain items whose fluctuations from period-to-period do not necessarily correspond to changes in the core operations of the business. Adjusted Income from Operations, Adjusted Operating Margin and Adjusted Net Income (including Adjusted Diluted Earnings per Share) are used by management and the Board to assess the Company's business. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. Also, other companies might calculate these measures differently. Investors are encouraged to review the reconciliations of the non-GAAP financial measures to their most directly comparable GAAP measures included on slides 18-20 in the appendix of this presentation.

Preliminary InVentiv Health Financial Results The financial data relating to inVentiv Health's quarter ended March 31, 2017 is preliminary and has been prepared by, and is the responsibility of inVentiv Health's management. Neither inVentiv Health's independent registered public accounting firm nor any other independent registered public accounting firm has audited, reviewed or compiled, examined or performed any procedures with respect to the estimated results, nor have they expressed any opinion or any other form of assurance on the preliminary estimated financial results. This preliminary information reflects management's estimates based solely upon information available as of the date of this presentation and is not a comprehensive statement of inVentiv Health's financial results for the three months ended March 31, 2017. The information presented herein should not be considered a substitute for the full unaudited first quarter financial statements. There is a possibility that actual results will vary from these preliminary estimates.

INC Research + inVentiv Health Purpose built to address market realities where clinical and commercial must work together – sharing expertise, data and insights – to improve customer performance Infusing clinical insights into commercialization, and commercial expertise into clinical trials, to speed the delivery of evidence-based medicines to patients worldwide

Transformational Strategic Combination Industry Leader # 7 CRO # 6 CRO / #1 CCO Top 3 CRO / #1 CCO Strength in SMID Biopharma; limited penetration in Top 20 Biopharma Strength with Top 20 Biopharma Diversified and highly complementary customer base Therapeutic focus in oncology, CNS and Infectious Disease Therapeutic focus in oncology (solid tumors), CNS and Respiratory Therapeutic depth and expertise, particularly complex diseases Full Service focus Hybrid / FSP delivery model Flexibility and depth to serve customers of all sizes and needs Critical mass in North America / EMEA; Sub-scale in APAC Critical mass in North America, EMEA and APAC Global leader including APAC; Top 3 global CRO in Japan RWE capabilities #1 CCO with growing RWE and data analytics capabilities Comprehensive suite of end-to-end drug development solutions Strong infrastructure; Trusted Process® Additional scale and resources Substantial scale, 22,000+ FTEs One of the most comprehensive offerings in terms of scale, therapeutic depth and expertise, delivery model flexibility, geographic coverage and customer relationships

Creates the #2 Global Biopharmaceutical Solutions Company Capability A leading global Clinical Research Organization (“CRO”) A leading global CRO and Contract Commercial Organization (“CCO”) Capability Capability ~\$3.2 billion 2016 Combined Net Revenue \$600+ million 2016 Combined Adjusted EBITDA (before cost synergies) 22,000+ employees Employees in 60+countries Serving customers in 110+countries Serving all top 50 biopharma Clinical Commercial Full Service Early Stage Functional Service Provider (“FSP”) Communications Selling Solutions Consulting Medication Adherence ~\$60bn Total Addressable Market (~50% outsourcing penetration) ~\$150bn Total Addressable Market (~16% outsourcing penetration) 2016 Net Revenue of ~\$2.1bn Adj. EBITDA margin of ~21% 2016 Net Revenue of ~\$1.2bn Adj. EBITDA margin of ~18% Top 3 CRO based on net revenue #1 CCO based on net revenue Significant number of top 50 biopharma utilize clinical and commercial services of combined company, with attractive opportunity to further penetrate existing base plus SMID Biopharma customers

Significant Value Creation Opportunities Mid-to-high single digit accretion in 2018 20% plus accretion in 2019 and beyond Numerous opportunities to further enhance revenue growth and margin expansion not reflected above Accelerating inVentiv Health margin expansion story Identified and achievable annual cost synergies of ~\$100 million Significant free cash flow generation supports rapid deleveraging to under 3x within 18-24 months post-close Up to an additional \$50 million of potential cost synergies not included in accretion estimates Additional margin enhancement opportunities Meaningful revenue synergies from cross-selling in clinical and commercial Identified tax assets and opportunities Pro forma 17-20 growth Revenue – high single digits EBITDA – mid teens EBITDA margin expansion – ~300 bps EPS – high teens 2017-2020 Combined Outlook High-single digits Net Revenue growth Mid-teens Adjusted EBITDA growth ~300bps Adjusted EBITDA margin expansion High-teens Adjusted EPS growth

Key Transaction Highlights Consideration Ownership Timing Management Headquarters Board of Directors INC Research to issue common stock to inVentiv Health in an all-stock transaction Values inVentiv Health at an enterprise value of ~\$4.6bn and combined company at an enterprise value of ~\$7.4bn based on closing price of INC Research common stock on May 9, 2017 Implied 2017 and 2018 Adjusted EBITDA transaction multiple of ~11x and ~10x, respectively (including present value of inVentiv Health NOL) Headquartered in Raleigh, North Carolina with a significant presence in the Northeast corridor INC Research shareholders will own 53% of the combined company inVentiv Health shareholders, including Advent International and Thomas H. Lee Partners, will own 47% Expected to close in 2H 2017 Subject to INC Research shareholder approval, regulatory approval and customary closing conditions Michael Bell to be Executive Chairman (current Chief Executive Officer of inVentiv Health) Alistair Macdonald to be Chief Executive Officer (current Chief Executive Officer of INC Research) Greg Rush to be Chief Financial Officer (current Chief Financial Officer of INC Research) Ten member Board Five to be designated by INC Research (including Alistair Macdonald) Five to be designated by inVentiv Health (including Michael Bell and representatives of Advent International and Thomas H. Lee Partners)

Employees(2) 50,000 22,000+ 10,000 15,000(3) 18,500 15,200 18,600 9,100 9,200 12,500 13,000 7,300 6,900 8,000
2,500 (Covance) Note:Trademarks, service marks or trade names are the property of their respective owners. (1)Pro
forma for estimated 2016 Capsugel net revenue. Foreign exchange conversion as of 12/31/16 (0.9839 USD per CHF).
(2) Latest available employee data; rounded for presentation purposes. (3)Only includes Covance employees. (4)Net
Revenue figure represents LTM 9/30/16 and foreign exchange conversion as of 9/30/16 (1.1238 USD per EUR). ~ ~
(\$ in billions) 2016 Biopharmaceutical Solutions Net Revenue Global Biopharmaceutical Solutions Leader in Size and
Scale

A Leader in End-to-End Drug Development Solutions Real World Evidence Data Analytics Selling Solutions
Comm-unications Consulting Central Lab FSP Full Service Phases II-IV Phase I Medication Adherence
Note:Trademarks, service marks or trade names are the property of their respective owners. Shading represents
estimated meaningful presence in selected capabilities; selected companies ordered by outsourcing revenue (excluding
the combined company). CRO CCO (Ashfield) (Covance)

A Strong, Well Diversified Business Ability to Serve Customers of All Sizes Comprehensive End-to-End Solutions
Diversified Customer Base Solutions Mix CRO CCO Biopharma Customer Concentration (Total Company)
Biopharma Customer Type (Total Company) Top 5 Other Top 6-10 Top 20 SMID Top 21-50 Note: Above based on
2016 combined company's net revenue including clinical and commercial segments. (1) Small to mid-sized biopharma.
(1)

Consulting Clinical Visibility and Therapeutic Experience Inform Commercialization Efforts Commercial Pricing & Marketing Insights and Enterprise Data Inform Clinical Design & Execution Selling Solutions Consulting Early Stage Full Service Strategic Resourcing CCO CRO Communications Medication Adherence Platform to Leverage Insights Across Continuum Improves Performance Integrated approach allows commercial insights to inform and enhance clinical trial design Proprietary data assets and communications capabilities enhance speed and success of site selection and patient recruitment while providing critically important real-world evidence capabilities Award winning site relationships expedite clinical trials and provide bridge to physician awareness and education Broad suite of capabilities bridges clinical gap and more effectively communicates clinical benefits to payers / PBMs Cross-selling opportunity between inVentiv Health and INC Research's existing customers

Clinical Research Organization Segment

Critical Success Factors in Today's Global Clinical Development Market
Critical Scale Strong Geographic Presence
Therapeutic Depth and Expertise Delivery Model Flexibility Ability to Deliver Solutions for Customers of All Sizes
Understanding Market Challenges Building a better CRO to service customers

Creates a Global Leader in Clinical Outsourcing Critical Scale (Covance) Clinical Development Net Revenue(1) CRO Employees (~15,400) Support customers in 110+ countries Employees in 60+ countries 2,500+ employees in APAC ~400 in Japan (top 3 global CRO in Japan) ~250 in China ~1,200 in India Strong Geographic Presence US / Canada Central / South America EMEA APAC Note:Trademarks, service marks or trade names are the property of their respective owners. Above based on 2016 combined company clinical net revenue. (1)Excludes revenue contribution from Central Laboratories based on company filings and market research. (\$ in billions)

Therapeutic Area Depth and Breadth of Delivery Models Ability to deliver solutions for all customer needs
Therapeutically-aligned delivery model provides industry-leading full service offering Increasing customer desire for hybrid models Leading FSP offering with ~\$500mm of annual net revenue, of which ~\$200mm is clinical monitoring and project management Utilize Trusted Process® Deep expertise across all therapeutic areas, particularly in complex diseases to meet needs of the largest biopharma customers Expanded expertise in oncology (both solid and liquid tumors) and CNS Oncology revenue of >\$500mm CNS revenue of >\$700mm Expanded capabilities in cardiovascular & metabolic and respiratory Therapeutic Depth and Expertise Net Revenue by Therapeutic Area Net Revenue by Service Area Delivery Model Flexibility Oncology CNS General Medicine CV & Met Respiratory Other Full Service FSP Note: Above based on 2016 combined company clinical net revenue.

Flexibility to Serve Customers of All Sizes Combination of inVentiv Health's strength with top 20 complements INC Research strength with SMID Strong stable revenue base from top 50 – ~\$1.4bn combined net revenue A leader in serving SMID biopharma with ~\$700mm net revenue, a segment INC Research has grown awards at ~25% CAGR since 2012 Combined top 5 and 10 customers ~31% and ~46% of clinical net revenue, respectively Ability to Deliver Solutions for Customers of All Sizes Understanding Market Challenges Top 20 SMID Top 21-50 Note: Above based on 2016 combined company clinical net revenue. (1) INC Research, according to CenterWatch. Net Revenue by Biopharmaceutical Customer Type Preferred partner to sites and investigators Ranked top CRO to work with by sites (1) Depth of therapeutic insights Enhance customer ability to design protocol Improve R&D efficiency Faster recruitment and patient enrollment Enhance commercial success Bring market access insights into trial/protocol design Control brand during R&D Patient advocacy, issues management, study branding Demonstrate therapeutic value Real world evidence capability enhanced by commercial services

Contract Commercial Organization Segment

Growth in the CRO market has historically been in the high single digits, with the CCO market projected to follow a similarly strong growth path Biopharma sales and marketing budgets are significant – at least 10% greater than R&D budgets at large biopharma Shift toward specialty and more complex therapies requires more complex and integrated sales and marketing execution/experience Significant outsourcing penetration opportunity – ~16% of commercialization spending is currently outsourced Evolving landscape illustrated by witnessed shift to longer and more strategic relationships Projected CCO Market Development Commercial Spending Landscape ~16% outsourcing penetration Commercial Market Offers Attractive Growth Profile (\$ in billions) CAGR: ~8% CCO Market % Outsourcing Penetration (\$ in billions) Source:Based on management estimates, public company filings and market research.

Biopharmaceutical Operating Challenges Demand New Commercial Solutions Margin deterioration Fewer blockbusters with shift to specialty Global shift of care from volume to value Reimbursement and access hurdles R&D productivity Growing political pressures Reduce SG&A Optimize deployment of marketing and field assets Refocus product portfolios around therapeutic areas with depth of presence Expand market access and pharmacoeconomic capabilities Thought leaders particularly focused on: Expanding scale / range of commercial outsourcing Coordinating and integrating execution across sales & marketing disciplines Challenges Existing Approaches Evolving Solutions Combined company well-positioned to deliver solutions to meet evolving needs

Broadest Provider of Commercialization Solutions Selling Solutions Communications Consulting Medication Adherence CCO Employees: ~6,400 Net Revenue: \$1,186mm Adjusted EBITDA margin of ~18% #1 organization in US Largest independent global healthcare agency Pharmacy network covering ~194 million patients and 2.2 billion Rxs/year Supported 70+ product launches over the past 5 years Field-based promotional solutions Strategy design, recruitment, deployment, and end to end sales operations Healthcare advertising Medical communications Digital marketing Communications planning PR and branding services Commercial strategy and planning Pricing and market access Medical affairs advisory, and risk and program management Highly flexible direct-to-patient programs Designed to help patients stay on their prescribed therapy Data-driven methodology Note:Information above refers to inVentiv Health.

Leading Global Provider Focused on High Value Commercial Solutions Selling Solutions P P P Communications P – P Consulting P P P Medication Adherence P – Limited Data + Insight P P P 2016 net revenue(1) \$1,186 \$796 \$528 2016 net revenue growth(1) 12% (6%) 5% 2016 Adjusted EBITDA margin(1)(2) ~18% 9% 15% Key financial metrics (\$ in millions) / (Commercial only) (Integrated Engagement Services) (Ashfield) (Tactical) Source:Company filings and materials. Note:Trademarks, service marks or trade names are the property of their respective owners. (1)2016 figures for Ashfield represent LTM 9/30/16 and foreign exchange conversion as of 9/30/16 (1.1238 USD per EUR). (2)Adjusted EBITDA figures for Integrated Engagement Services segment of QuintilesIMS represent EBIT. QuintilesIMS does not allocate D&A to its various segments when reporting. As a leading CCO, we possess the platform necessary to drive consistent growth and deliver the end-to-end capabilities necessary to compete in the evolving market

Expansive Data Assets Can Drive Insights and Improve Execution Physician targeting and segmentation Site selection and patient recruitment Observational studies and Real World Evidence Multi-channel promotion opportunities Medication adherence programs Protocol design and feasibility Trial protocol burden Electronic medical records Clinical performance Trial saturation Patient journey Pharmacy claims Longitudinal Rx Prescriber interaction / preference Market access / competitive landscape Patient and healthcare provider insights

Financial Highlights

'14-'17 CAGR: 9% '14-'17 CAGR: 48% '14-'17 CAGR: 21% Significantly Accelerates Growth Revenue Adjusted EBITDA Adjusted EPS INC Research Standalone INC Research + inVentiv Health 2017 – 2020 CAGR 2017 – 2020 CAGR 2017 – 2020 CAGR Significantly increases addressable market Highly diversified revenue sources Does not include revenue synergies from cross-selling No expected revenue disynergy amongst shared customers Driven by inVentiv Health margin expansion and cost synergy realization, including Trusted Process® efficiencies Does not reflect additional potential cost synergies and margin enhancement opportunities Earnings growth enhanced by efficient capital structure and deleveraging via free cash flow Mid-to-high single digit accretion in 2018 20% plus accretion in 2019 and beyond Note: 2017 estimates based on INC Research's guidance and not actual results.

Identifiable and Achievable Cost Synergies and Meaningful Additional Upsides Tax Opportunities Cost Synergies
Additional Margin Enhancement Opportunities Improve effective tax rate from combined of 35% to low 30's inVentiv
Health net operating losses of ~\$850mm Corporate and administrative spending Rationalize clinical cost structure
Facility consolidation IT systems consolidation Therapeutic delivery model implemented within inVentiv Health full
service offering Utilize Trusted Process® Leverage best-in-class capabilities from each CRO platform Consolidating
multiple clinical operational systems, where appropriate ~\$100 million run-rate cost synergies fully realized within
three years post-close Additional upsides not included in synergies or accretion estimates Up to an additional \$50
million of potential cost synergies not included in accretion estimates

Meaningful Revenue Synergies From Cross-Selling Cross-Sell Commercial Offering to Clinical Customer Base Market Combined Clinical Scale and Service Offering Utilize Commercial Insights, Data and Relationships to Increase Clinical Win-Rate INC Research's SMID customer base represents customer set currently underpenetrated Traditional co-promote with large pharma costs companies 30-50% economics and limits flexibility in Ventiv Health's hybrid and FSP offering into INC Research's installed customer base Combined FSP offering spans monitoring, data, analytics, PVG, safety and investigator payments Stronger therapeutic area breadth and scale driving more access to top 50 biopharma Comprehensive solution offering into biopharma C-Suite Strategic consulting engagements provide early access to and relationships with decision makers Ability to provide real-world insights and enhanced evidence based packages to bridge the gap between clinical and commercial Ability to leverage a comprehensive suite of offerings at different value proposition to increase clinical win rate and deepen relationships Significant number of top 50 biopharma utilize clinical and commercial services of combined company, with attractive opportunity to further penetrate existing base plus SMID Biopharma customers

Value Creation Through Successful Integrations 7 acquisitions since 2007 25 acquisitions since 2007 MDS Global
Clinical Development Kendle International 2011 2009 \$41mm \$56mm \$9mm \$12mm PharmaNet / i3 2011 \$28mm
\$35mm 2012-2016 Value Creation 31% +910bps 20% +740bps Year Forecast Cost Synergies Cost Synergies
Achieved Adj. EBITDA CAGR Adj. EBITDA Margin Expansion 2 of which were transformational 2 of which were
transformational

Strong Pro Forma Credit Profile Plan to opportunistically refinance capital structure, affording favorable terms, liquidity and flexibility Long-term focus on deleveraging and optimizing weighted average cost of debt, including reducing inVentiv Health Unsecured Notes 4.0x pro forma net leverage at time of closing(1) Highlights Strong free cash flow generation to drive rapid deleveraging New Term Loan B(2) \$2.6 Equity Issued to inVentiv Health 2.2 Total Sources \$4.8 inVentiv Equity Purchase Price 2.2 inVentiv Health Term Loan 1.7 INC Research Total Debt 0.5 Repay inVentiv Health Unsecured Notes 0.3 Transaction Expenses 0.1 Total Uses \$4.8 Pro Forma Cap Table(3) (\$ in billions) Cash \$0.2 New Term Loan B \$2.6 Senior Unsecured Notes 0.4 Capital Leases 0.1 Total Debt \$3.1 Net Debt / Pro Forma Adjusted EBITDA(1) 4.0x (1)Based on PF LTM 3/31 Adjusted EBITDA, including \$100 million of run-rate synergies. (2) Assumes the entry into a new Term Loan B credit facility to be done on a best efforts basis (the "Best Efforts Financing"). In the event the Best Efforts Financing cannot be consummated, inVentiv Health would use the proceeds from a committed \$550 million incremental term loan under its existing credit facility to prepay INC Research's total debt. In such event, the inVentiv Health Term Loan would remain outstanding and the inVentiv Health Unsecured Notes would not be redeemed in part. (3)As of 3/31/17. Anticipated Sources & Uses (\$ in billions)

INC Research Q1 2017 Highlights Key Operating Metrics – Adjusted Basis Record quarter of net awards of ~\$360mm, creating book-to-bill of 1.4x and returning INC Research to strong backlog growth of 12% Awards were broad based, including \$86mm Safety FSP award and \$55M from 2 new preferred provider relationships Revenue of \$252mm, above the mid-point of guidance Strong operational execution drove EBITDA margin of 23.1%, above our guidance range \$mm (except ratios and per share data) Three Months Ended March 31, 2016 2017 % Change Total Company: Net Service Revenue 249.0 252.1 1.2% Adjusted EBITDA 57.1 58.1 1.8% Adjusted EBITDA margin 22.9% 23.1% ~20bps Adjusted EPS \$0.58 \$0.60 3.4% Selected Clinical Metrics: Net New Business Awards 302.4 359.9 19.0% Book-to-Bill Ratio 1.2x 1.4x LTM Book-to-Bill Ratio 1.3x 1.2x Backlog 1,874 2,103 12.2%

Creating a Leading Global Biopharmaceutical Solutions Organization Top 3 CRO / #1 CCO Diversified and highly complementary customer base Deep therapeutic expertise, particularly complex diseases Flexibility and depth to serve customers of all sizes and needs Global leader including APAC; Top 3 global CRO in Japan Comprehensive suite of end-to-end drug development solutions Substantial scale with 22,000+ FTEs Substantial value creation via synergies, attractive earnings accretion and enhanced growth

Appendix

Commercial Business is Well-Positioned for Growth New drug approvals have been on a steady increase over the past decade however timing of approvals can be lumpy 2016 decline (~50%) only 3rd down year since 2007 and well in excess of historical average decline of (26%) Approximately 70 compounds scheduled for potential approval this year Worked with ~80% of drugs approved over last 5 years, between Clinical and Commercial Launched more drugs than any other outsourced provider or pharma company since 2011 5-Year Average: 35 NDAs Decline in NDAs during 2016 expected to reverse during 2017 Approved to date On pace to exceed average and recent high Source:FDA and inVentiv Health and INC Research Managements. Note:2017 YTD as of 5/9/17.

INC Research Q1 2017 Income Statement Income Statement – Adjusted Basis Note: Due to rounding of specific line items, line item figures might not sum to subtotals. For a complete reconciliation of GAAP to Non-GAAP measures for the current and historical periods presented, please refer to slides 36-38 in the appendix of this presentation. \$mm (except margin and per share data) Three Months Ended March 31, 2016 2017 % Change Net Service Revenue \$249.0 \$252.1 1.2% Direct Costs 150.0 152.1 1.4% Gross Profit 99.0 100.0 1.0% Gross Profit Margin 39.8% 39.7% -10 bps Selling, General and Administrative 41.9 41.8 (0.2%) Depreciation 4.9 6.2 26.0% Income from Operations 52.2 52.0 (0.4%) Income from Operations Margin 21.0% 20.6% -40 bps Interest Expense, net (3.0) (3.0) 0.6% Income before Provision for Income Taxes 49.2 49.0 (0.5%) Income Tax Expense (16.7) (15.9) (4.9%) Net Income \$32.5 \$33.1 1.8% Diluted EPS \$0.58 \$0.60 3.4% EBITDA \$57.1 \$58.1 1.8% EBITDA Margin 22.9% 23.1% +20 bps

INC Research Backlog Should Support Long-Term Growth Note: Due to rounding of specific line items, line item figures might not sum to subtotals. (1) 2017 revenue estimate represents the mid-point of the updated guidance range on slide 35 of this presentation. (2) CNS was updated during Q2 2016 to include Ophthalmology as a complex disease area. (3) Backlog burn represents current quarter net revenue divided by previous quarter ending backlog.

| | Q2 '16 | Q3 '16 | Q4 '16 | Q1 '17 |
|-----------------------------|---------|---------|---------|---------|
| Beginning Backlog (\$mm) | \$1,874 | \$1,909 | \$1,983 | \$1,988 |
| Acquired Backlog (\$mm) | 0 | 0 | 0 | 0 |
| Net Awards (\$mm) | 302 | 330 | 290 | 360 |
| Revenue, as reported (\$mm) | (259) | (260) | (263) | (252) |
| FX Adjustment (\$mm) | 4 | (22) | 7 | |
| Ending Backlog (\$mm) | \$1,909 | \$1,983 | \$1,988 | \$2,103 |

Backlog by Therapeutic Area (2) Backlog Coverage (\$mm)

| Therapeutic Area | 3/31/15 | 3/31/16 | 3/31/17 |
|------------------------|---------|---------|---------|
| Oncology | 88.2% | 90.8% | 90.7% |
| Other Complex Diseases | | | |
| Central Nervous System | | | |

Backlog Burn Rate (3) (As of March 31, 2017) CNS, Oncology and other Complex Diseases = 71% of Backlog

Backlog as of: 3/31/15 3/31/16 3/31/17 Coverage Ratio

YoY Revenue Growth 13.0% 12.6% 2.4%

2015A 2016A 2017E Revenue ROY Backlog

INC Research Full Year 2017 Guidance Note: Financial guidance takes into account a number of factors, including INC Research sales pipeline, existing backlog and expectations for net awards, current foreign currency exchange rates, current interest rates, and expected tax rate, and does not take into account the effects of any future stock repurchases. For a reconciliation of GAAP Net Income and diluted earnings per share to Non-GAAP Net Income and diluted earnings per share, please refer to slide 37 in the appendix of this presentation. (1) Guidance for Net Service Revenue includes foreign exchange headwind of approximately \$15.0M (a negative impact of approximately 150 basis points) resulting in a constant currency growth rate of approximately 2.4 – 5.3%. (2) 2017 growth rates are based on adjusted 2016 financials, with the exception of GAAP Diluted EPS. Guidance Issued 2/28/2017 Guidance Issued 5/10/2017 Financial Measurement Guidance Range Growth Rate(2) Guidance Range Growth Rate(2) Net Service Revenue(1) \$ 1,030.0 - 1,100.0M 0.0 - 6.8% \$ 1,040.0 - 1,070.0M 0.9 - 3.8% Adjusted Net Income \$ 146.5 - 153.5M 5.4 - 10.4% \$ 147.5 - 152.0M 6.1 - 9.3% Adjusted Diluted EPS \$ 2.63 - 2.75 5.2 - 10.0% \$ 2.66 - 2.74 6.4 - 9.6% GAAP Diluted EPS \$ 1.94 - 2.10 (4.4) - 3.4% \$ 2.04 - 2.15 0.5 - 5.9%

INC Research Q2 2017 Guidance 36 Note: Financial guidance takes into account a number of factors, including INC Research sales pipeline, existing backlog and expectations for net awards, current foreign currency exchange rates, current interest rates, and expected tax rate, and does not take into account the effects of any future stock repurchases. For a reconciliation of GAAP Net Income and diluted earnings per share to Non-GAAP Net Income and diluted earnings per share, please refer to slide 38 in this presentation Guidance Issued 5/10/2017 Financial Measurement Guidance Range Net Service Revenue \$ 250.0 - 260.0M Adjusted Net Income \$33.0 - 36.5M Adjusted Diluted EPS \$ 0.60 - 0.66 GAAP Diluted EPS \$ 0.38 - 0.44

INC Research FY 2017 Guidance Reconciliation 37 Adjustments are estimates with an estimated range of +/- 5% and are presented gross without the benefit of income tax reduction. Income tax effect of share-based compensation is calculated using the statutory rates applicable to the tax jurisdictions of the applicable deduction, plus the amount of discrete tax adjustments related to excess tax benefits on share-based payments as a result of share-based payments activity. Income tax expense is calculated and the adjustments are tax-affected at an approximate rate of 32%, which is the midpoint of our range for the expected income tax rate of 31% to 33%. This adjustment also excludes any unusual tax impacts during the period. Adjusted Net Income Adjusted Diluted Earnings Per Share Low High Low High Net Income and Diluted EPS \$113.0 \$119.5 \$2.04 \$2.15 Adjustments: Amortization(1) 28.5 28.5 Share-based Compensation Expense(1) 24.0 24.0 Restructuring, CEO transition and other costs(1) 7.0 7.0 Other(1) 4.8 4.4 Income tax effect of share-based compensation(2) (11.0) (11.0) Income tax effect of above adjustments(3) (18.8) (20.4) Adjusted Net Income and Adjusted Diluted EPS \$147.5 \$152.0 \$2.66 \$2.74

INC Research Q2 2017 Guidance Reconciliation 38 Adjustments are estimates with an estimated range of +/- 5% and are presented gross without the benefit of income tax reduction Income tax expense is calculated and the adjustments are tax-affected at an approximate rate of 32%, which is the midpoint of our range for the expected income tax rate of 31% to 33%. This adjustment also excludes any unusual tax impacts during the period. Adjusted Net Income Adjusted Diluted Earnings Per Share Low High Low High Net Income and Diluted EPS \$21.0 \$24.5 \$0.38 \$0.44 Adjustments: Amortization(1) 9.5 9.5 Share-based Compensation Expense(1) 6.7 6.7 Restructuring, CEO transition and other costs(1) 4.0 4.0 Income tax effect of above adjustments(2) (8.2) (8.2) Adjusted Net Income and Adjusted Diluted EPS \$33.0 \$36.5 \$0.60 \$0.66

INC Research Non-GAAP Financials \$mm Fiscal Year Ending December 31, 2014 2015 2016 Q1 '16 Q1 '17 LTM Net
Income (loss) (\$23.5) \$117.0 \$112.6 \$17.4 \$21.2 \$116.4 Interest expense, net 52.8 15.4 11.8 3.0 3.0 11.8 Income tax
provision (benefit) (4.7) 13.9 21.5 7.0 7.1 21.6 Depreciation and Amortization 54.5 56.0 59.3 14.4 15.7 60.5 EBITDA
\$79.1 \$202.4 \$205.1 \$41.7 \$46.9 \$210.3 Restructuring and other costs (a) 6.2 1.8 13.6 6.0 1.9 9.5 Stock based
compensation (b) 3.4 5.1 14.0 2.8 5.8 17.0 Transaction expenses (c) 7.9 1.6 3.1 0.6 0.0 2.6 Goodwill and intangible
assets impairment (d) 17.2 3.9 - - - Contingent consideration and other (e) 0.9 0.6 1.7 0.8 - 0.9 Monitoring and
advisory fees (f) 0.5 - - - - Other expense (income) (g) (7.7) (3.9) 9.0 5.1 3.5 7.3 Loss on extinguishment of debt (h)
46.8 9.8 0.4 - - 0.4 Change order adjustment (i) (9.0) - - - - R&D tax credit adjustment (j) - - (2.5) - - (2.5) Adjusted
EBITDA \$145.3 \$221.4 \$244.5 \$57.1 \$58.1 \$245.6 Note:See page 41 for detailed information.

INC Research Non-GAAP Financials (Cont'd) \$mm Fiscal Year Ending December 31, 2014 2015 2016 Q1 '16 Q1 '17

| | | | | | | | | | | | | |
|----------------------------|---------|---------|---------|--|--------------|---|---------|---------|----------------------------|--|-------------------------------|--------------------------|
| Net Income (loss) (\$23.5) | \$117.0 | 112.6 | \$17.4 | \$21.2 | Amortization | 32.9 | 37.9 | 37.9 | 9.5 | 9.5 | Restructuring and other costs | |
| (a) | 6.2 | 1.8 | 13.6 | 6.0 | 1.9 | Stock based compensation (b) | 3.4 | 5.1 | 14.0 | 2.8 | 5.8 | Transaction expenses (c) |
| | 7.9 | 1.6 | 3.1 | 0.6 | 0.0 | Goodwill and intangible assets impairment (d) | 17.2 | 3.9 | - - - | Contingent consideration and other (e) | 0.9 | 0.6 |
| | 1.7 | 0.8 | - | - | - | Monitoring and advisory fees (f) | 0.5 | - - - - | Other expense (income) (g) | (7.7) | (3.9) | 9.0 |
| | 5.1 | 3.5 | - | - | - | Loss on extinguishment of debt (h) | 46.8 | 9.8 | 0.4 | - - | Change order adjustment (i) | (9.0) |
| | - - - - | - - - - | - - - - | - - - - | - - - - | R&D tax credit adjustment (j) | - - | (2.5) | - - | Adjust income tax to normalized rate (k) | (31.0) | (53.7) |
| | (50.9) | (9.7) | (8.8) | Adjusted Net Income | \$44.6 | \$120.2 | \$139.0 | \$32.5 | \$33.1 | Adjusted diluted net income per share | \$0.83 | \$2.00 |
| | \$2.50 | \$0.58 | \$0.60 | Diluted weighted average common shares | 53.9 | 60.1 | 55.6 | 55.9 | 55.1 | Note:See page 41 for detailed information. | | |

INC Research Non-GAAP Financials (Cont'd) (a)Restructuring, CEO transition, and other costs consist primarily of: (i) severance costs associated with a reduction of workforce in line with the Company's expectations of future business operations, (ii) transition costs associated with the change in the Company's Chief Executive Officer during the fourth quarter of 2016, (iii) consulting costs incurred for the continued consolidation of legal entities and restructuring of the Company's contract management process to meet the requirements of upcoming accounting regulation changes, and (iv) termination costs in connection with abandonment and closure of redundant facilities and other lease related charges. (b)Represents share-based compensation expense related to awards granted under equity incentive plans. (c) Represents fees associated with stock repurchases and secondary stock offerings, debt placement and refinancings, IPO costs, and other corporate transactions. (d) Represents impairment of goodwill, intangible assets and long-lived assets associated with our Global Consulting, a component of the Clinical Development segment, and Phase I Services reporting units. (e) Represents contingent consideration expense incurred as a result of acquisitions and other expenses accounted for as compensation expense under GAAP (f) Represents monitoring and advisory fees paid to affiliates of Avista Capital Partners, L.P. in the periods prior to the initial public offering in November 2014, as well as reimbursements of expenses paid to affiliates of Avista Capital Partners, L.P. and affiliates of Teachers' Private Capital pursuant to the Expense Reimbursement Agreement. These arrangements were terminated upon completion of our initial public offering. (g) Represents other (income) expense comprised primarily of foreign exchange gains and losses. (h) Represents loss on extinguishment of debt associated with the Company's debt refinancing activities in November 2014, May 2015, and August 2016. (i) During the second and third quarters of 2014, we experienced higher-than-normal change order activity estimated to be between \$6M and \$12M. Adjusted EBITDA, Adjusted Net Income, and Adjusted diluted earnings per share for 2014 have been adjusted by \$9M to remove the impact of this higher-than-normal change order activity. (j)Represents research and development tax credits in certain international location for expenses incurred during 2016 and recorded as a reduction of direct costs. We have not received similar level of research and development credits in prior years as the associated costs did not qualify. Accordingly, we have excluded these expenses for 2016. (k) Represents the income tax effect of the non-GAAP adjustments made to arrive at adjusted net income using an estimated effective tax rate of approximately 32.5% for the first quarter of 2017, 34% in 2016, 36% in 2015, and 37% in 2014. This rate has been adjusted to reflect the removal of the tax impact of valuation allowances recorded against deferred tax assets

inVentiv Health Financial Overview (\$ in millions) CAGR: 10% (\$ in millions) CAGR: 29% % margin CAGR: 6% CAGR: 26% % margin CAGR: 15% CAGR: 22% % margin Mid-single digit Adjusted EBITDA growth Double-digit growth in clinical Commercial/corporate down mid-single digits due to double digit revenue declines offset by margin improvements 2017 revenue impacted by large cancel in Q4 and near-decade low new drug approvals Pipeline and expected new product approvals support return to historical growth in 2018+ Net Revenues Adjusted EBITDA 2017 Outlook Total Clinical Commercial Note: Clinical and Commercial segment information does not include impact of eliminations or corporate adjustments.

inVentiv Health Estimated and Preliminary Q1 2017 Highlights \$mm (except ratios) Three Months Ended March 31, 2016 2017 % Change Total Company: Net Service Revenue 541.3 533.8(1) (1.4%) Adjusted EBITDA 85.0 96.7 13.7% Adjusted EBITDA margin 15.7% 18.1% ~240bps Selected Clinical Metrics: Net New Business Awards 296.8 306.0 3.1% Book-to-Bill Ratio 1.2x 1.1x LTM Book-to-Bill Ratio 1.2x 1.1x Backlog 2,100 2,258 7.5% Strong organic clinical net revenue growth of 7%(2) Commercial business impacted by a large customer cancelation (product removed from market) in Q4 and near-decade low (22) new drug approvals in 2016 New product approval pipeline (20 YTD) provides significant new business opportunity in late 2017 and beyond Continued success on Adjusted EBITDA margin expansion initiatives drove ~240bps improvement to 18.1% Robust pipeline of clinical strategic partnership opportunities across customer types Key Operating Metrics – Adjusted Basis (1)Excludes the impact of \$7.8mm of purchase accounting. (2)Excludes the impact of \$6.7mm of purchase accounting and \$2.3mm of FX.

inVentiv Health Non-GAAP Financials \$mm Fiscal Year Ending December 31, 2013 2014 2015 2016 Q1 '16 Q1 '17

LTM Net Income (loss) (\$236.4) (\$188.8) (\$150.6) (\$183.6) (\$18.6) (\$40.7) (\$205.7) Interest expense, net 209.2
 217.0 228.2 231.7 55.9 37.7 213.6 Income tax provision (benefit) 3.0 2.5 5.6 (8.2) 8.2 (14.7) (31.0) Depreciation and
 Amortization 106.0 107.3 95.1 116.1 23.8 84.5 176.9 EBITDA \$81.8 \$138.1 \$178.3 \$156.1 \$69.2 \$66.8 \$153.8
 Impairment loss (a) 38.9 24.0 69.2 68.0 - - 68.0 Stock based compensation (b) (0.8) 0.6 4.3 30.1 1.1 4.6 33.5 Impact
 of acquisition accounting adjustments (c) 2.1 (4.2) 1.8 20.3 0.4 10.9 30.8 Management fees (d) 2.8 2.5 2.7 3.7 0.9 1.2
 4.0 Foreign currency transaction (gains)/losses (e) (0.0) 0.3 0.6 (8.8) 2.1 2.9 (8.0) Impact of unrestricted subsidiaries
 net of addbacks (f) 3.7 4.6 3.0 0.7 0.3 - 0.4 Acquisition and financing expense (g) 2.1 0.3 1.4 54.1 0.6 0.6 54.1
 Severance (h) 12.4 13.7 10.8 8.3 2.7 2.9 8.5 Restructuring costs (i) 14.6 10.9 8.2 10.2 2.5 1.7 9.4 Other Investment (j)
 - 0.8 5.2 16.9 4.4 0.0 12.5 Discontinued operations (k) 20.2 8.2 - - - - Purchase price finalization (l) (14.2) - - - - -
 Other (m) 4.8 7.0 (4.3) 5.0 0.9 5.0 9.1 Adjusted EBITDA \$168.3 \$206.8 \$281.1 \$364.5 \$85.0 \$96.7 \$376.2 Note: See
 page 45 for detailed information. Q1 '17 is based on estimated and preliminary data.

inVentiv Health Non-GAAP Financials (Cont'd) (a)Represents non-cash losses associated with the impairment of goodwill, intangible assets and other long-lived assets. (b)Represents stock-based compensation charges in the income statement. (c)Represents non-cash adjustments resulting from the revaluation of certain items such as deferred revenue and deferred rent recognized in connection with our prior acquisitions. (d)Represents the annual sponsor management fee paid pursuant to the THL and Advent Management Agreement described in our consolidated financial statements with our annual report for the year ended December 31, 2016. (e)Represents the net gain or loss resulting from currency remeasurements. (f)Represents the loss from continuing operations of certain subsidiaries that we previously designated as unrestricted for purposes of our debt instruments. (g)Represents legal and advisory fees incurred in connection with strategic transactions and financings that do not relate to and are not indicative of our core on-going operations. (h)Represents employee termination costs. (i)Represents costs in connection with facility closures, relocations, integrations and business optimization. (j)Represents costs incurred in connection with the Apria Agreement. (k)Represents the results of operations for our medical management and sample management business, which were classified and presented as discontinued operations in our financial statements in 2013 and 2014. (l)Represents the final purchase price adjustment recorded in the second quarter of 2013 related to the acquisition of United Health Group's clinical development business (the "i3 Acquisition"). (m)Represents third party costs for tax services, franchise taxes, certain non-cash items, one time costs from third party advisors, gain (loss) on extinguishment of debt, gain (loss) on the divestiture of iPAS in the third quarter of 2015, and equity investment income.